Zobrazeno 1 - 10
of 164
pro vyhledávání: '"B. Yvonnet"'
Publikováno v:
Médecine et Maladies Infectieuses. 45:29-33
Objectives Rapid testing for tetanus on serum or blood allows for an immediate evaluation of individual protection against tetanus in developed countries, using a “single step” immunochromatographic technique using tetanus toxoid. The specificity
Publikováno v:
Journal of Medical Virology. 73:474-480
Human papillomavirus (HPV) virus-like particles (VLP) and synthetic peptides corresponding to positively-charged sequences of the major and minor capsid proteins were tested for their efficacy in inhibiting the infectivity of HPV 31 pseudovirions by
Autor:
D. Leboulleux, P. Coursaget, I. Diop-Mar, M. T. Diop, A.M. Coll-Seck, B. Yvonnet, M. Soumare, O. Bao, P. Le Cann, J. P. Chiron
Publikováno v:
Journal of Gastroenterology and Hepatology. 8:S128-S133
Hepatitis B virus (HBV) infection and related diseases represent some of the major public health problems in Senegal. The prevalence of hepatitis B surface antigen (HBsAg) in infants increased steadily during their first years of life. HBsAg prevalen
Autor:
M, Schlumberger, B, Yvonnet, Huong Vu Thi, Que, Dy Bun, Chhem, P, Saliou, Thi Cam, Le Tu, P, Glaziou
Publikováno v:
Bulletin de la Societe de pathologie exotique (1990). 101(1)
In 1997, the Ministry of Health tested the feasibility and serological activity of a two-dose vaccine at one year interval within a catch-up tetanus immunization programme in a rural population. In the district of Angkor Thom in the Siem Reap provinc
Autor:
J. P. Chiron, I. Diop-Mar, C. Bourdil, O. Bao, C. Molinie, Y. Buisson, P. Coursaget, M. T. Diop, B. Yvonnet
Publikováno v:
Research in Virology. 141:563-570
Antibodies to the preS1-encoded sequence of hepatitis B virus (HBV) envelope were detected by ELISA using a synthetic peptide analogue of preS1 proteins, in different groups of HBV-infected subjects and also in hepatitis B vaccine recipients. Such an
Autor:
C. Bourdil, J. P. Chiron, Marie-Pascale Frenkiel, B. Yvonnet, Pierre Coursaget, S. Guindo, E. Jeannée, L. Teulières, Edgar H. Relyveld, A. Brizard, I. Diop-Mar, B. Fritzell
Publikováno v:
Vaccine. 10:319-321
In most developing countries, hepatitis B virus is endemic and prevention has to be carried out early in life and on a mass scale. In these regions, simultaneous administration of multiple antigens is normal practice. We have therefore investigated t
Autor:
R. N'Doye, C. Molinie, Y. Busson, J. Chotard, C. Bourdil, J. P. Chiron, I. Diop-Mar, B. Yvonnet, Pierre Coursaget
Publikováno v:
Vaccine. 8:S15-S17
A new type of hepatitis B virus (HBV) infection has been encountered in Senegalese infants and French adults characterized by serum hepatitis B surface antigen (HBsAg) without antibodies to the core antigen (anti-HBc). As the infection is not associa
Publikováno v:
Périodiques Scientifiques en Édition Électronique.
Philippe Maupas : Hepatitis B vaccine discoverer « Philippe Maupas Day » 8th february 1981, an official ceremony with all the Profession, the Tours Faculty of Pharmacy was called Philippe Maupas, Hepatitis B vaccine discoverer - Galien Prize 1981.
Autor:
Pierre Le Cann, I. Diop-Mar, B. Yvonnet, Anna-Marie Coll-Seck, Masserigné Soumare, D. Leboulleux, J. P. Chiron, Pierre Coursaget
Publikováno v:
Journal of hepatology. 21(2)
Numerous studies have documented the efficacy and safety of plasma-derived and recombinant hepatitis B vaccines. However, little is known about the long-term protection of hepatitis B vaccine, when anti-HBs declines to low or undetectable levels. Thi
Publikováno v:
Biometrics. 49(2)
Analysis of longitudinal studies is often complicated through differences amongst individuals in the number and spacing of observations. Laird and Ware (1982, Biometrics 38, 963-974) proposed a linear random-effects model to deal with this problem. W